Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Clinical trial NCT07224360 · RECRUITING

Trial details

NCT number: NCT07224360
Sponsor: CSL Behring
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Sickle Cell Disease

Start date: 2026-02-02
Primary completion: 2028-06-29
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.